Analysts wary of Biogen's strategy as earnings, Alzheimer's data loom
"The path they're pursuing just seems to me to have too much risk," Baird analyst Brian Skorney told the Business Journal.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Allison DeAngelis Source Type: news